): Developmental Funds NCCC uses discretionary funds in general, and CCSG Developmental Funds in particular, to pursue new opportunities, promote novel transdisciplinary collaborations, and advance meritorious cancer research. In response to the 2008 review, we have retained a priority for investment in new faculty recruitment, where return on investment historically has been highest. Refinement in use of Developmental Funds has been linked to insights arising from planning and evaluation activities. In response to External Advisor recommendations, we have emphasized collaborative initiatives, and Members subsequently have secured an NCI U54 award in Cancer Nanotechnology and NIGMS P20 IDeA multi-project awards in quantitative biomedical sciences and in molecular epidemiology. NCCC utilizes its five-year Strategic Plan to prioritize announcements and financing of projects requesting use of developmental funds. The full portfolio of NCCC developmental approaches includes pilot projects, new faculty funding, interim support, and investment in advanced technology and new Shared Resource services. Recipients of pilot awards totaling $687,853 in CCSG funds secured $16.3M in subsequent funding (see Table 2). We have directed pilot project awards to strategic areas, such as multi-investigator proposals, translational studies, and early phase clinical trials. We have examples of faculty refocusing on cancer-relevant questions (e.g., Stan [CM]), teams subsequently securing multi-investigator awards (e.g., Roberts, Paulsen, and Pogue [CIR]), and junior faculty securing peer- reviewed support (e.g., Danilov [MT]). During the current award period, we received renewal with a 25% increase in the ACS-IRG pilot award program NCCC conducts. Our most recent call for pilot projects secured proposals from over 25% of our Members, indicating the value perceived in this opportunity, and we selected 8 of 24 proposals, including at least one from each Program. We have invested $315,000 in CCSG funds in new faculty recruitments who have secured $10.8M in subsequent peer-reviewed funding (see Table 3). NCCC has in place policies addressing bridging (resubmission of approved but unfunded proposals) and retention (preparation of new proposals) support, both of which rely on NCCC discretionary funds rather than CCSG support. We have utilized NCCC developmental funds to promote Member utilization of new technologies, including deep-sequencing and preclinical imaging. We have augmented services available to Members through existing NCCC Shared Resources by developing new capabilities, such as geospatial mapping and speed congenics. Renewal of CCSG Developmental Funds will support pilot project awards in priority areas such as translational research, new faculty recruitment in strategic initiatives in early phase clinical development and cancer immunotherapy, the 2015 opening of the NCCC-directed floor in the adjacent Williamson Translational Research Building, and collaborative groups around emerging themes such as precision medicine, surgical innovation, and behavioral interventions aimed at cancer risk reduction.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA023108-40
Application #
9616812
Study Section
Subcommittee I - Career Development (NCI)
Project Start
Project End
Budget Start
2018-12-01
Budget End
2019-11-30
Support Year
40
Fiscal Year
2019
Total Cost
Indirect Cost
Name
Dartmouth College
Department
Type
DUNS #
041027822
City
Hanover
State
NH
Country
United States
Zip Code
03755
Shee, Kevin; Jiang, Amanda; Varn, Frederick S et al. (2018) Cytokine sensitivity screening highlights BMP4 pathway signaling as a therapeutic opportunity in ER+ breast cancer. FASEB J :fj201801241R
Rodriguez-Garcia, Marta; Fortier, Jared M; Barr, Fiona D et al. (2018) Aging impacts CD103+ CD8+ T cell presence and induction by dendritic cells in the genital tract. Aging Cell 17:e12733
Shajani-Yi, Zahra; de Abreu, Francine B; Peterson, Jason D et al. (2018) Frequency of Somatic TP53 Mutations in Combination with Known Pathogenic Mutations in Colon Adenocarcinoma, Non-Small Cell Lung Carcinoma, and Gliomas as Identified by Next-Generation Sequencing. Neoplasia 20:256-262
Szczepiorkowski, Zbigniew M; Burnett, Christine A; Dumont, Larry J et al. (2018) Apheresis buffy coat collection without photoactivation has no effect on apoptosis, cell proliferation, and total viability of mononuclear cells collected using photopheresis systems. Transfusion 58:943-950
Bossé, Yohan; Amos, Christopher I (2018) A Decade of GWAS Results in Lung Cancer. Cancer Epidemiol Biomarkers Prev 27:363-379
Pande, Mala; Joon, Aron; Brewster, Abenaa M et al. (2018) Genetic susceptibility markers for a breast-colorectal cancer phenotype: Exploratory results from genome-wide association studies. PLoS One 13:e0196245
Smith, T Jarrod; Sondermann, Holger; O'Toole, George A (2018) Co-opting the Lap System of Pseudomonas fluorescens To Reversibly Customize Bacterial Cell Surfaces. ACS Synth Biol 7:2612-2617
Gorlova, Olga Y; Li, Yafang; Gorlov, Ivan et al. (2018) Gene-level association analysis of systemic sclerosis: A comparison of African-Americans and White populations. PLoS One 13:e0189498
Schmit, Stephanie L; Edlund, Christopher K; Schumacher, Fredrick R et al. (2018) Novel Common Genetic Susceptibility Loci for Colorectal Cancer. J Natl Cancer Inst :
Cai, Yunliang; Wu, Shaoju; Zhao, Wei et al. (2018) Concussion classification via deep learning using whole-brain white matter fiber strains. PLoS One 13:e0197992

Showing the most recent 10 out of 1911 publications